An updated review on the utility of hematopoietic stem cell transplant in the treatment of refractory myasthenia gravis
DOI:
https://doi.org/10.17161/rrnmf.v6i1.22987Keywords:
stem cell, hematopoietic stem cells, hematopoietic stem cell transplant, Myasthenia Gravis, refractory myasthenia gravisAbstract
INTRODUCTION: Hematopoietic stem cell transplantation (HSCT) has been shown to be an effective treatment in many severe autoimmune diseases. There have been a number of reported cases of successful HSCT in severe, refractory myasthenia gravis (MG).
OBJECTIVE: To review and summarize the current literature on the role of HSCT in the management of refractory MG.
METHODS: Databases including PubMed, clinical trials.gov, and Cochrane Reviews were searched for research articles containing “hematopoietic stem cell transplantation,” “stem cell,” and “myasthenia gravis.” Articles were excluded if they were not written in English.
RESULTS: A total of 16 patients across 8 publications were identified as having undergone HSCT in the setting of MG. Following HSCT, all patients had significant improvement in their MG status, with 11 achieving complete stable remission. Common adverse effects were mostly infection-related and included neutropenic fever, cytomegalovirus viremia or reactivation, mucositis, and upper respiratory tract infection.
CONCLUSION: HSCT has the potential to provide sustained benefit for patients with MG who are refractory to conventional treatment. A large-scale prospective study is warranted to better define its role in the treatment of MG.
Metrics
Downloads
References
Gwathmey KG, Burns TM. Myasthenia Gravis. Semin Neurol. 2015;35(4):327-339. doi:10.1055/s-0035-1558975.
Rodrigues E, Umeh E, Aishwarya, Navaratnarajah N, Cole A, Moy K. Incidence and prevalence of myasthenia gravis in the United States: A claims-based analysis. Muscle Nerve. 2024;69(2):166-171. doi:10.1002/MUS.28006.
Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86(2):255-260. Published 2013 Jun 13.
Silvestri NJ, Wolfe GI. Treatment-Refractory Myasthenia Gravis. J Clin Neuromuscul Dis. 2014;15(4):167-178. doi:10.1097/CND.0000000000000034.
Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci. 2008;1132:305-314. doi:10.1196/annals.1405.033.
Mariottini A, Bulgarini G, Cornacchini S, Damato V, Saccardi R, Massacesi L. Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update. Bioengineering (Basel). 2023;10(2). 176. doi:10.3390/BIOENGINEERING10020176.
Greco R, Labopin M, Badoglio M, Veys P, Silva JMF, Abinun M, Gualandi F, Bornhauser M, Ciceri F, Saccardi R, Lankester A, Alexander T, Gennery AR, Bader P, Farge D, Snowden JA. Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. Front Immunol. 2009;10. doi:10.3389/FIMMU.2019.01570.
Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, … Saccardi R. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurol. 2017;74(4): 459-469. doi:10.1001/JAMANEUROL.2016.5867.
Sormani MP, Muraro PA, Schiavetti I, Signori A, Laroni A, Saccardi R, Mancardi GL, Capello E, Uccelli A, Bagigalupo F, Repice AM, Portaccio E, Barillaro A, Russo C, de Luca G, Farina D, Tartaro A, Blanco Y, Berenguer J, … Zonari P. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. Neurology. 2017;88(22):2115-2122. doi:10.1212/WNL.0000000000003987.
Boffa G, Massacesi L, Inglese M, Mariottini A, Capobianco M, Moiola L, Amato MP, Cottone S, Gualandi F, de Gobbi M, Greco R, Scimè R, Frau J, Zimatore GB, Bertolotto A, Comi G, Uccelli A, Signori A, Angelucci E, … Mancardi G. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology. 2021;96(8): E1215–E1226. doi: 10.1212/WNL.0000000000011461.
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88(9):842-852. doi:10.1212/WNL.0000000000003660.
Beland B, Hahn C, Jamani K, Chhibber S, White C, Atkins H, Storek, J. Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti-muscle specific kinase antibodies. Muscle Nerve. 2023;67(2):154-157. doi:10.1002/MUS.27772.
Bryant A, Atkins H, Pringle CE, Allan D, Anstee G, Bence-Bruckler I, Hamelin L, Hodgins M, Hopkins H, Huebsch L, McDiarmid S, Sabloff M, Sheppard D, Tay J, Bredeson C. Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurol. 2016;73(6):652-658. doi:0.1001/JAMANEUROL.2016.0113.
Håkansson I, Sandstedt A, Lundin F, Askmark H, Pirskanen R, Carlson K, Piehl F, Hägglund H. Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis – a case report. Neuromuscul Disord. 2017;27(1):90-93. doi:10.1016/j.nmd.2016.09.020.
Inan B, Bekircan-Kurt CE, Demiroǧlu H, Göker H, Erdem-Özdamar S, Tan E. Autologous stem cell transplantation in a patient with refractory anti-MuSK-Positive myasthenia gravis and familial mediterranean fever. Neurol. Sci. Neurophysiol. 2022;39(2):115-118. doi:10.4103/NSN.NSN_197_21.
Mitsumune S, Manabe Y, Yunoki T, Kono S, Aoyama K, Shinno Y, Narai H, Abe K. Autologous Bone Marrow Transplantation for Polymyositis Combined with Myasthenia Gravis and Aplastic Anemia: A Case Report. Case Rep Neurol. 2018;10(1):108-111. doi:10.1159/000488476.
Schlatter MI, Yandamuri SS, O’Connor KC, Nowak RJ, Pham MC, Obaid AH, Redman C, Provost M, McSweeney PA, Pearlman ML, Tees MT, Bowen JD, Nash RA, Georges GE. Remission of severe myasthenia gravis after autologous stem cell transplantation. Ann Clin Transl Neurol. 2023;10(11):2105-2113. doi:10.1002/ACN3.51898.
Sossa Melo CL, Peña AM, Salazar LA, Jiménez SI, Gómez ED, Chalela CM, Ayala-Castillo M, Peña IM. Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report. Neuromuscul Disord. 2019;29(2):142-145. doi:10.1016/j.nmd.2018.11.008.
Strober J, Cowan MJ, Horn BN. Allogeneic Hematopoietic Cell Transplantation for Refractory Myasthenia Gravis. Arch Neurol. 2009;66(5):659-661. doi:10.1001/ARCHNEUROL.2009.28.
Burman J, Tolf A, Hägglund H, Askmark H. Autologous haematopoietic stem cell transplantation for neurological diseases. J Neurol Neurosurg Psychiatry. 2018;89(2):147-155. doi:10.1136/jnnp-2017-316271.
Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn KW, Sullivan KM, Carrum G, Andrey J, Bredeson CN, Cairo M, Gale RP, Hahn T, Storek J, Horowitz MM, McSweeney PA, Griffith LM, Muraro PA, Pavletic SZ, Nash RA. Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2012;18(10):1471-1478. doi: 10.1016%2Fj.bbmt.2012.06.003.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Grace Li BA, Morgan Heber MD, Tiffany Pike-Lee MD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
